Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer.
OBJECTIVE
This study is to investigate the role of miR-143 expression in cervical squamous cell carcinoma (SCC).


METHODS
The expression level of miR-143 was examined by quantitative real-time PCR. Human papillomavirus (HPV) genotype was detected by HPV genotype detection kit. The expression level of bcl-2 was detected by immunohistochemistry.


RESULTS
The positive rate of HPV was 78% in the patients of cervical SCC. The most prevalent genotype was HPV16, with a positive rate of 42%. The expression level of miR-143 was significantly lower in the cervical SCC tissues than that in the normal cervical tissues (Z=-2.180, P=0.029). Down-regulated miR-143 expression was associated with tumor size, lymph node metastasis and HPV16 infection in cervical cancer patients. No significant associations were found between the expression levels of miR-143 and age, clinical stage, differentiation or lymph vascular space invasion. And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was higher and the positive expression of bcl-2 protein was lower. However, the differences in expression changes of miR-143 and bcl-2 were not statistically significant (miR-143, Z=-0.763, P=0.446; bcl-2 protein, χ2=2.277, P=0.131).


CONCLUSIONS
Down-regulated miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical SCC, but miR-143 does not participate in the Taxol sensitivity response.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1401279451112150.
Yanxia
Y
Chen
Department of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, No, 137 Liyushan South Road, Urumqi, Xinjiang 830054, P,R, China. chenyanxiacyx@sina.cn.
Cailing
C
Ma
Wei
W
Zhang
Zhifang
Z
Chen
Li
L
Ma
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary / Q000821:virology; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D002681:China; D004279:DNA, Viral / Q000302:isolation & purification; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D061809:Human Papillomavirus DNA Tests; D052162:Human papillomavirus 16 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000032:analysis*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000627:therapeutic use; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000821:virology*; D060888:Real-Time Polymerase Chain Reaction; D016896:Treatment Outcome; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000821:virology
D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D004279:DNA, Viral; C542359:MIRN143 microRNA, human; D035683:MicroRNAs; D017239:Paclitaxel